Stock listing

NASDAQ:IRD Opus Genetics, Inc. Stock

Home listing (NASDAQ) of Opus Genetics, Inc.

Follow Opus Genetics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IRD

$3.99 USD +0.07 (+1.8%)

Close on Nov 20, 2026

Past year +106.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.89 – $4.05 USDNov 20, 2026
Volume
1.19M sharesNov 20, 2026
Market cap
$385.7M USDAt the close on Nov 20, 2026 · price × 96.65M shares outstanding
52-week range
$1.86 – $7.07 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$12.70M USDMedian day 1.36M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Opus Genetics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IRD · Home$3.99 USD+0.07 (+1.8%)1,185,998$4.01$4.045$3.89$3.92Close on Nov 20, 2026
Frankfurt:R3X1€3.58 EUR-0.08 (-2.2%)—€3.72€3.72€3.50€3.66Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IRD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.99+0.07+1.8%$4.01$4.045$3.891,185,998
$3.92-0.13-3.2%$4.05$4.13$3.90751,009
$4.05+0.01+0.2%$4.02$4.079$3.915729,169
$4.04+0.06+1.5%$3.94$4.08$3.885975,012
$3.98-0.08-2.0%$4.05$4.17$3.80747,347
$4.06-0.25-5.8%$4.23$4.35$3.961,387,753
$4.31+0.08+1.9%$4.31$4.52$4.131,206,811
$4.23+0.03+0.7%$4.19$4.27$4.041,069,930
$4.20+0.02+0.5%$4.24$4.365$4.1541,145,651
$4.18+0.175+4.4%$4.02$4.24$4.01784,408
$4.005-0.265-6.2%$4.26$4.26$3.7951,473,772
$4.27+0.34+8.7%$4.05$4.31$3.981,162,209
$3.93+0.23+6.2%$3.74$3.99$3.741,129,709
$3.70+0.03+0.8%$3.69$3.78$3.615877,656
$3.67+0.02+0.5%$3.58$3.69$3.421,019,544
$3.65-0.03-0.8%$3.68$3.82$3.60709,585
$3.68+0.22+6.4%$3.44$3.69$3.401,033,143
$3.46+0.14+4.2%$3.32$3.53$3.281,303,301
$3.32-0.15-4.3%$3.49$3.50$3.231,520,145
$3.47-0.35-9.2%$3.79$3.83$3.441,115,336
$3.82-0.295-7.2%$4.04$4.10$3.80894,736
$4.115+0.105+2.6%$4.03$4.215$4.001,355,925
$4.01+0.19+5.0%$3.82$4.145$3.781,461,227
$3.82-0.02-0.5%$3.87$3.94$3.691,527,758
$3.84-0.21-5.2%$4.12$4.13$3.752,527,000
$4.05-0.05-1.2%$4.15$4.28$3.982,952,900
$4.10-0.14-3.3%$4.40$4.40$4.081,198,400
$4.24-0.40-8.6%$4.76$4.77$4.231,291,500
$4.64-0.01-0.2%$4.63$4.88$4.601,623,200
$4.65+0.19+4.3%$4.46$4.74$4.451,255,400
$4.46+0.05+1.1%$4.41$4.48$4.251,345,700
$4.41+0.03+0.7%$4.35$4.66$4.251,839,800
$4.380.000.0%$4.47$4.48$4.192,534,000
$4.38-0.20-4.4%$4.57$4.64$4.342,534,900
$4.58+0.07+1.6%$4.56$4.67$4.451,789,500
$4.51-0.33-6.8%$4.89$4.91$4.511,873,800
$4.84-0.12-2.4%$4.96$5.32$4.832,458,000
$4.96-0.09-1.8%$5.07$5.15$4.801,525,100
$5.05+0.29+6.1%$4.75$5.14$4.631,161,400
$4.76-0.11-2.3%$4.89$4.93$4.701,244,700
$4.87+0.04+0.8%$4.76$4.96$4.601,831,200
$4.83-0.33-6.4%$5.14$5.16$4.653,055,100
$5.16-0.06-1.1%$5.20$5.30$5.041,172,000
$5.22+0.04+0.8%$5.17$5.55$5.171,979,800
$5.18-0.10-1.9%$5.29$5.34$5.115,541,000
$5.28-0.13-2.4%$5.46$5.62$5.231,531,100
$5.41-0.41-7.0%$5.80$5.80$5.352,335,200
$5.82-0.15-2.5%$5.94$5.95$5.671,991,900
$5.97-0.07-1.2%$6.02$6.22$5.802,550,100
$6.04-0.03-0.5%$6.16$6.58$5.774,652,000
$6.07+0.34+5.9%$5.87$6.24$5.406,536,900
$5.73+1.39+32.0%$5.31$7.07$5.3154,319,700
$4.34-0.33-7.1%$4.53$4.62$4.312,267,600
$4.67+0.07+1.5%$4.53$4.80$4.402,239,600
$4.60+0.15+3.4%$4.66$4.83$4.284,425,600
$4.45+0.62+16.2%$3.86$4.52$3.864,994,700
$3.83+0.21+5.8%$3.65$3.85$3.59868,600
$3.62-0.07-1.9%$3.71$3.72$3.51584,100
$3.69-0.16-4.2%$3.85$3.86$3.63823,600
$3.85+0.05+1.3%$3.80$3.92$3.79546,100
$3.80-0.31-7.5%$4.17$4.21$3.77908,700
$4.11+0.08+2.0%$4.07$4.42$4.041,496,000
$4.03-0.02-0.5%$4.02$4.24$3.82812,200
$4.05-0.07-1.7%$4.16$4.33$4.021,045,000
$4.12+0.05+1.2%$4.01$4.26$4.011,461,500

Splits

3 splits since 2017 · NASDAQ:IRD · every price before a split is adjusted for it

DayRatioWhat
1-for-4Consolidation
1-for-12Consolidation
1-for-10Consolidation
Ticker
NASDAQ:IRD
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Opus Genetics, Inc. news

Opus Genetics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
40 in the last 12 months · 79 in all · newest Nov 19, 2026 · oldest 2021
Decks
33 decks · latest November 2026

Where Opus Genetics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IRD · Home listing · This pageNASDAQUnited StatesUSD
gettex:R3X1gettexGermanyEUR
LS Exchange:A2QG4ZLS ExchangeGermanyEUR
Frankfurt:R3X1FrankfurtGermanyEUR
Lang & Schwarz:A2QG4ZLang & SchwarzGermanyEUR
BOATS:IRDBOATSUnited StatesUSD
Tradegate:R3X1TradegateGermanyEUR
Dusseldorf:R3X1DusseldorfGermanyEUR
Munich:R3X1MunichGermanyEUR
Stuttgart:R3X1StuttgartGermanyEUR

Valuation

EV/sales 42.0× against a median of 23.0×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$332.3M USD
P/E
Loss
EV/sales
42.0×
EV/EBITDA
Negative EBITDA
Price/book
10.0×
Gross margin
99.8%
Operating margin
−777.7%
Net margin
Revenue too small
Debt to equity
0.9×
Beta vs S&P 500
1.01

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Opus Genetics, Inc. · NASDAQ:IRDUS$385.7MUS$332.3Mn/a42.0×n/a10.0×n/a0.9×1.01
Ever Supreme Bio Technology Co., Ltd. · TPEX:6712US$394.8MUS$362.8M27.5×11.1×23.9×4.6×43.8%0.0×n/a
Mezzion Pharma Co., Ltd. · KRX:140410US$391.0MUS$360.8Mn/a57.3×n/a13.4×−325.0%0.0×n/a
Avalo Therapeutics, Inc. · NASDAQ:AVTXUS$390.9M−US$1.93Mn/an/an/a0.9×n/a0.0×1.25
Qurient Co., Ltd. · KRX:115180US$388.5MUS$372.4Mn/a70.5×n/a30.2×−543.0%0.8×n/a
Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480US$388.2MUS$369.1Mn/an/an/a4.3×n/a0.4×n/a
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378US$387.5MUS$316.0Mn/an/an/a4.1×n/a0.1×n/a
Eupraxia Pharmaceuticals, Inc. · TSX:EPRXUS$384.3MUS$252.7Mn/an/an/a2.9×n/a0.0×1.53
Hinova Pharmaceuticals, Inc. Class A · SSE:688302US$381.1MUS$285.9Mn/a23.0×n/a2.6×−167.3%0.1×n/a
Rezolute, Inc. · NASDAQ:RZLTUS$379.2MUS$289.9Mn/an/an/a4.4×n/a0.0×1.28
Phathom Pharmaceuticals, Inc. · NASDAQ:PHATUS$378.8MUS$359.8Mn/a1.3×n/an/a−30.2%n/a1.08
Median of the othersUS$387.9MUS$337.9M27.5×23.0×23.9×4.3×−167.3%0.0×1.27

Forecasts

15 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
13.59 USD · Analysts' mean
EPS, year to Dec 2026
-1.24 · 4 analysts
Revenue, year to Dec 2026
14.14M · 17 analysts

Team and board

Officers

OfficerRole
George MagrathChief Executive Officer
Robert GagnonChief Financial Officer
Joe SchachleChief Operating Officer
Andrew MurphyChief Scientific Officer
Ben Yerxa
Chris ErnstChief Technology Officer
Sally TuckerChief Medical Officer
Sarah TullerChief Regulatory Officer

Board

DirectorRole
Cam GallagherChairman of the Board
Adrienne Graves
Ben Yerxa
Richard RodgersDirector
Susan Benton

Events

QuarterResultsShare move
Q3 2026Nov 10, 2026 · Before open+0.7%
Q2 2026Aug 6, 2026 · Before open−1.6%
Q1 2026May 12, 2026 · Before open+1.2%
Q4 2025Feb 25, 2026−1.4%
Q3 2025Nov 12, 2025 · Before open−2.5%
Q2 2025Aug 13, 2025 · After close+7.3%
Q1 2025May 15, 2025 · Before open0.0%
Q4 2024Mar 31, 2025−9.9%
Q3 2024Nov 12, 2024 · Before open−2.6%
Q2 2024Aug 13, 2024 · Before open−21.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · After close−2.3%
Q4 2023Mar 8, 2024−12.2%
Q3 2023Nov 13, 2023 · Before open+1.8%
Q2 2023Aug 11, 2023 · Before open+1.9%
Q1 2023May 15, 2023−18.9%
Q4 2022Mar 30, 2023 · After close−2.1%
Q3 2022Nov 4, 2022 · After close−5.0%
Q2 2022Aug 12, 2022 · Before open−9.0%
Q1 2022May 13, 2022 · Before open+8.0%
Q4 2021Mar 24, 2022+11.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck50 slidesNovember 2026
Retina in Rio 2026Conference25 slidesOct 15, 2026
Corporate Update (October 2026)Corporate update12 slidesOct 15, 2026
Investor Presentation (October 2026)Investor deck50 slidesOctober 2026
Euretina 2026Conference11 slidesOctober 2026
Retina Forum 2026Conference15 slidesSep 30, 2026
Technical Presentation (September 2026)Technical36 slidesSep 9, 2026
Technical Presentation (September 2026)Technical39 slidesSep 9, 2026
Technical Presentation (June 2026)Technical80 slidesJun 16, 2026
Technical Presentation (May 2026)Technical24 slidesMay 13, 2026
All 33 decks
DeckKindSlidesDate
Technical Presentation (February 2026)Technical16 slidesFeb 27, 2026
Investor Presentation (January 2026)Investor deck29 slidesJan 12, 2026
Technical Presentation (September 2025)Technical30 slidesSep 30, 2025
Ocuphire Pharma — Merger or Acquisition (October 2024)Merger or acquisition27 slidesOct 22, 2024
Ocuphire Pharma — Technical Presentation (May 2024)Technical14 slidesMay 10, 2024
Ocuphire Pharma — Investor Presentation (March 2024)Investor deck30 slidesMar 27, 2024
Ocuphire Pharma — Investor Presentation (November 2023)Investor deck42 slidesNov 2, 2023
Ocuphire Pharma — Investor Presentation (August 2023)Investor deck42 slidesAug 1, 2023
Ocuphire Pharma — Investor Presentation (May 2023)Investor deck27 slidesMay 15, 2023
Ocuphire Pharma — Corporate Update (January 2023)Corporate update31 slidesJan 25, 2023
Ocuphire Pharma — Technical Presentation (October 2022)Technical53 slidesOct 14, 2022
Ocuphire Pharma — Investor Presentation (August 2022)Investor deck46 slidesAug 12, 2022
Ocuphire Pharma — Investor Presentation (May 2022)Investor deck59 slidesMay 19, 2022
Ocuphire Pharma — Corporate Update (March 2022)Corporate update37 slidesMar 29, 2022
Ocuphire Pharma — Investor Day (January 2022)Investor day114 slidesJan 31, 2022
Ocuphire Pharma — Investor Presentation (January 2022)Investor deck50 slidesJan 5, 2022
Ocuphire Pharma — Investor Presentation (November 2021)Investor deck57 slidesNov 15, 2021
Ocuphire Pharma — Investor Presentation (August 2021)Investor deck53 slidesAug 12, 2021
Ocuphire Pharma — Technical Presentation (June 2021)Technical33 slidesJun 30, 2021
Ocuphire Pharma — Technical Presentation (March 2021)Technical29 slidesMar 15, 2021
Ocuphire Pharma — Investor Presentation (January 2021)Investor deck37 slidesJan 6, 2021
Rexahn Pharmaceuticals — Investor Presentation (November 2020)Investor deck37 slidesNov 6, 2020
Rexahn Pharmaceuticals — Investor Presentation (September 2015)Investor deck33 slidesSep 10, 2015

Open Decks

Financings

RaiseDate
Private placement of series B Non-Voting Convertible Preferred Stock
Announced: US$25M · US$3.39 a share
Buyers: Adage Capital Management; Trails Edge Capital Partners; Marshall Wace
Use of proceeds: Advance gene therapy clinical programs, working capital and general corporate purposes
Feb 13, 2026
Registered direct offering of equity securities
Closed: US$23M raised · US$2.09 a share
Buyers: Perceptive Advisors (led the financing); Balyasny Asset Management (led the financing); Nantahala Capital (participated)
Use of proceeds: Advance LCA5 and BEST-1 gene therapy clinical programs, working capital and general corporate purposes
Nov 12, 2025
Public offering of shares of common stock, or common stock equivalents, and warrants
Closed: US$20M raised · US$0.95 a share · Warrants at US$0.95 for 60 months · Craig-Hallum
Dealers: Craig-Hallum (lead)
Buyers: Perceptive Advisors; Nantahala Capital
Use of proceeds: Extending cash runway and funding key upcoming milestones for the gene therapy portfolio
Mar 31, 2025
Private placement of shares of common stock and warrants
Closed: US$1.5M raised · US$1.275 a share · Warrants at US$1.15 for 60 months
Buyers: George Magrath; Cam Gallagher
Insiders: CEO George Magrath and board chairman Cam Gallagher participated
Use of proceeds: Clinical development of OPGx-LCA5 and OPGx-BEST1 gene therapy programs, general corporate purposes and working capital
Mar 31, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue14.2M11.0M19.0M39.9M589.0K03.00M
Cost of revenue53.0K10.0K6.00K4.00K4.00K8.00K
Gross profit14.2M11.0M19.0M39.9M589.0K-8.00K
Research and development30.8M26.9M17.7M14.4M15.2M6.65M5.48M13.1M10.7M10.1M
Selling, general and administrative22.0M18.2M12.0M7.27M8.12M2.82M1.82M
Operating income-38.6M-62.1M-10.6M18.2M-22.7M-20.0M-4.19M-20.5M-17.4M-16.4M
Depreciation and amortization53.0K10.0K6.00K4.00K4.00K8.00K41.0K48.2K42.4K32.9K
EBITDA-38.5M-62.1M-10.6M18.2M-22.7M-20.0M-4.15M-20.5M-17.3M-16.4M
Interest expense129.0K009.00K2.00K6.85M1.41M
Income before tax-49.6M-57.5M-9.97M18.2M-56.7M-24.6M-6.17M-14.4M-25.3M-9.31M
Income tax0012.0K315.0K000
Net income-49.6M-57.5M-9.99M17.9M-56.7M-24.6M-6.17M-14.4M-25.3M-9.31M
Earnings per share, basic-0.80-2.15-0.460.90-3.82-5.28-2.17-5.25-0.92-0.43
Earnings per share, diluted-0.80-2.15-0.460.87-3.82-5.28-2.17-5.25-0.92-0.43

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents45.1M30.3M50.5M42.6M24.5M16.4M1.54M8.74M8.90M11.6M
Short-term investments02.00K15.0K49.0K219.0K0
Receivables2.00M3.56M926.0K1.30M00125.0K
Current assets50.0M36.6M53.9M49.0M26.1M17.7M1.76M15.9M28.1M20.9M
Property, plant and equipment199.0K252.0K06.00K10.0K14.0K22.0K112.5K121.5K88.7K
Total assets50.2M36.9M53.9M49.0M26.1M17.7M1.78M16.0M28.3M21.0M
Accounts payable3.29M3.15M2.15M1.07M1.58M1.21M342.0K
Current liabilities7.78M11.3M4.04M2.75M3.85M3.19M9.34M3.15M
Long-term debt1.13M0
Total debt1.13M0538.0K5.67M
Total liabilities34.9M11.3M4.04M2.75M3.85M31.1M9.34M5.48M11.5M3.99M
Shareholders' equity15.3M6.72M49.9M46.2M22.2M-13.5M-7.56M-1.70M16.8M17.1M
Shares outstanding69.9M31.6M24.0M20.9M18.8M10.9M2.85M3.12M31.7M23.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-35.3M-25.6M-1.11M14.3M-19.4M-6.80M-3.59M-18.8M-15.4M-13.2M
Capital spending000000-25.0K
Free cash flow-35.3M-25.6M-1.11M14.3M-19.4M-6.80M-3.62M
Cash from investing01.21M00-100.0K539.0K-25.0K11.9M-9.37M4.48M
Cash from financing50.0M4.19M8.98M3.79M27.6M21.1M4.70M6.77M22.1M10.1M
Share buybacks-152.0K-79.0K0
Change in cash14.8M-20.2M7.87M18.1M8.13M14.9M1.09M-154.9K-2.68M1.38M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2026Quarterly reportSEC
8-K · Current reportNov 10, 2026ResultsSEC
4 · Change in ownershipNov 5, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
144 · Notice of proposed saleOct 23, 2026Other filingsSEC
144 · Notice of proposed saleOct 23, 2026Other filingsSEC
144 · Notice of proposed saleOct 23, 2026Other filingsSEC
8-K · Current reportOct 21, 2026Management or board changeSEC
8-K · Current reportOct 15, 2026Current reportSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipSep 11, 2026Insider tradeSEC
8-K · Current reportSep 11, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 17, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
CORRESP · Letter to the SECAug 13, 2026Other filingsSEC
UPLOAD · Letter from the SECAug 12, 2026Other filingsSEC
S-3 · Registration statementAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
4 · Change in ownershipJul 27, 2026Insider tradeSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
144 · Notice of proposed saleJul 23, 2026Other filingsSEC
424B2 · ProspectusJun 17, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJun 17, 2026Other filingsSEC
8-K · Current reportJun 16, 2026Current reportSEC
8-K · Current reportJun 16, 2026Current reportSEC
CORRESP · Letter to the SECJun 11, 2026Other filingsSEC
UPLOAD · Letter from the SECJun 10, 2026Other filingsSEC
S-3 · Registration statementJun 5, 2026Offer documentSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 20, 2026Big-stake noticeSEC
4 · Change in ownershipMay 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansMay 14, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
4 · Change in ownershipApr 27, 2026Insider tradeSEC
8-K · Current reportApr 24, 2026FinancingSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
144 · Notice of proposed saleApr 23, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 23, 2026Other filingsSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
4 · Change in ownershipApr 22, 2026Insider tradeSEC
8-K · Current reportApr 22, 2026Meeting outcomeSEC
CORRESP · Letter to the SECApr 21, 2026Other filingsSEC
S-3/A · Registration statement, amendedApr 20, 2026Offer documentSEC
8-K · Current reportApr 7, 2026Management or board changeSEC
8-K · Current reportApr 6, 2026Material contractSEC
ARS · Annual report to shareholdersMar 23, 2026Annual reportSEC
DEF 14A · Proxy statementMar 23, 2026Meeting noticeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
4 · Change in ownershipMar 18, 2026Insider tradeSEC
UPLOAD · Letter from the SECMar 17, 2026Other filingsSEC
144 · Notice of proposed saleMar 16, 2026Other filingsSEC
S-3 · Registration statementMar 13, 2026Offer documentSEC
PRE 14A · Preliminary proxy statementMar 12, 2026Meeting noticeSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 10, 2026ResultsSEC
8-K · Current reportFeb 19, 2026ResultsSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 22, 2026Offer documentSEC
4 · Change in ownershipJan 21, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipDec 31, 2025Insider tradeSEC
8-K · Current reportDec 19, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 11, 2025Big-stake noticeSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 6, 2025Material contractSEC
8-K · Current reportNov 6, 2025Current reportSEC
FWP · Free writing prospectusNov 6, 2025Offer documentSEC
424B5 · ProspectusNov 6, 2025Offer documentSEC
4/A · Change in ownership, amendedNov 5, 2025Insider tradeSEC
4 · Change in ownershipNov 4, 2025Insider tradeSEC
4 · Change in ownershipOct 24, 2025Insider tradeSEC
8-K · Current reportSep 30, 2025Current reportSEC
S-8 · Registration statement for employee plansSep 26, 2025Offer documentSEC
4 · Change in ownershipSep 11, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 11, 2025Insider tradeSEC
S-8 · Registration statement for employee plansSep 10, 2025Offer documentSEC
8-K · Current reportSep 2, 2025Management or board changeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
4 · Change in ownershipAug 27, 2025Insider tradeSEC
8-K · Current reportAug 25, 2025FinancingSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 11, 2025Big-stake noticeSEC
8-K · Current reportJul 23, 2025Material contractSEC
424B5 · ProspectusJun 26, 2025Offer documentSEC
8-K · Current reportJun 26, 2025Current reportSEC
8-K · Current reportJun 25, 2025Management or board changeSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 20, 2025Material contractSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 6, 2025Big-stake noticeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
8-K · Current reportMay 1, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialApr 14, 2025Meeting noticeSEC
PX14A6GApr 11, 2025Other filingsSEC
DEFA14A · Additional proxy materialApr 11, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 11, 2025Other filingsSEC
DEFA14A · Additional proxy materialApr 10, 2025Meeting noticeSEC
DFAN14AApr 9, 2025Other filingsSEC
CORRESP · Letter to the SECApr 9, 2025Other filingsSEC
CORRESP · Letter to the SECApr 8, 2025Other filingsSEC
S-3/A · Registration statement, amendedApr 8, 2025Offer documentSEC
CORRESP · Letter to the SECApr 7, 2025Other filingsSEC
DEFA14A · Additional proxy materialApr 7, 2025Meeting noticeSEC
8-K · Current reportApr 4, 2025Current reportSEC
424B5 · ProspectusApr 4, 2025Offer documentSEC
PRRN14AApr 4, 2025Other filingsSEC
DEFC14AApr 2, 2025Other filingsSEC
DFAN14AApr 2, 2025Other filingsSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeMar 31, 2025Big-stake noticeSEC
PRER14AMar 31, 2025Other filingsSEC
8-K · Current reportMar 31, 2025ResultsSEC
UPLOAD · Letter from the SECMar 28, 2025Other filingsSEC
DFAN14AMar 28, 2025Other filingsSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
4 · Change in ownershipMar 26, 2025Insider tradeSEC
8-K · Current reportMar 24, 2025FinancingSEC
424B5 · ProspectusMar 24, 2025Offer documentSEC
DFAN14AMar 21, 2025Other filingsSEC
PRER14AMar 21, 2025Other filingsSEC
PREC14AMar 21, 2025Other filingsSEC
FWP · Free writing prospectusMar 21, 2025Offer documentSEC
8-K · Current reportMar 20, 2025ResultsSEC
FWP · Free writing prospectusMar 20, 2025Offer documentSEC
424B5 · ProspectusMar 20, 2025Offer documentSEC
PREC14AMar 20, 2025Other filingsSEC
8-K · Current reportMar 20, 2025Current reportSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Opus Genetics, Inc.’s releases · as of Nov 6, 2026

Common shares
96,654,336
Fully diluted
96,654,336

Fully diluted

LineSharesAs of
Common shares96,654,336Nov 6, 2026

Warrants and options

Lot
Warrants · US$0.95 · expire about Mar 2030
Warrants · US$1.15 · expire about Mar 2030

Share count over time

CountShares
Nov 6, 202696,654,336
Sep 30, 202695,799,574

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Perceptive Advisors LLC9M9.3%US$43.6MSep 30, 2026
Caligan Partners LP5.96M6.2%US$28.9MSep 30, 2026
Cormorant Asset Management, LP5.5M5.7%US$26.6MSep 30, 2026
BlackRock5.24M5.4%US$25.3MSep 30, 2026
Vanguard4.61M4.8%US$22.3MSep 30, 2026
Nantahala Capital Management, LLC4.57M4.7%US$22.1MSep 30, 2026
Boxer Capital Management, LLC4.53M4.7%US$21.9MSep 30, 2026
Balyasny Asset Management L.P.3.73M3.9%US$18MSep 30, 2026
BIOS Capital Management, LP3.68M3.8%US$17.8MSep 30, 2026
Marshall Wace, LLP3.16M3.3%US$15.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Millennium3.14M3.2%US$15.2MSep 30, 2026
Trails Edge Capital Partners, LP2.41M2.5%US$11.7MSep 30, 2026
Adage Capital Partners Gp, L.L.C.2.25M2.3%US$10.9MSep 30, 2026
Geode Capital1.81M1.9%US$8.77MSep 30, 2026
ADAR1 Capital Management, LLC1.78M1.8%US$8.63MSep 30, 2026
State Street1.33M1.4%US$6.44MSep 30, 2026
Boothbay Fund Management, LLC1.17M1.2%US$5.65MSep 30, 2026
AWM Investment Company, Inc.1.05M1.1%US$5.09MSep 30, 2026
Logos Global Management LP1M1.0%US$4.84MSep 30, 2026
Blue Owl Capital Holdings LP970K1.0%US$4.69MSep 30, 2026
Affinity Asset Advisors, LLC900K0.93%US$4.36MSep 30, 2026
Goldman Sachs878K0.91%US$4.25MSep 30, 2026
Great Point Partners LLC777K0.80%US$3.76MSep 30, 2026
Opaleye Management Inc.750K0.78%US$3.63MSep 30, 2026
UBS723K0.75%US$3.5MSep 30, 2026
Woodline Partners LP662K0.68%US$3.2MSep 30, 2026
Northern Trust560K0.58%US$2.71MSep 30, 2026
Acuta Capital Partners, LLC514K0.53%US$2.49MSep 30, 2026
Citadel497K0.51%US$2.41MSep 30, 2026
Squarepoint Ops LLC353K0.37%US$1.71MSep 30, 2026
Susquehanna350K0.36%US$1.69MSep 30, 2026
XTX Topco Ltd287K0.30%US$1.39MSep 30, 2026
Propel Bio Management, LLC270K0.28%US$1.31MSep 30, 2026
Aureus Asset Management, LLC266K0.27%US$1.29MSep 30, 2026
Bleichroeder LP237K0.25%US$1.15MSep 30, 2026
Schwab204K0.21%US$988KSep 30, 2026
Morgan Stanley163K0.17%US$787KSep 30, 2026
BNY151K0.16%US$732KSep 30, 2026
Informed Momentum Co LLC146K0.15%US$705KSep 30, 2026
Two Sigma134K0.14%US$647KSep 30, 2026
Fidelity129K0.13%US$626KSep 30, 2026
Creative Planning129K0.13%US$624KSep 30, 2026
AQR Capital Management LLC121K0.12%US$584KSep 30, 2026
Texas Capital Bank Wealth Management Services Inc117K0.12%US$566KSep 30, 2026
Nuveen115K0.12%US$558KSep 30, 2026
Bank of America109K0.11%US$527KSep 30, 2026
Sei Investments Co105K0.11%US$510KSep 30, 2026
Stonepine Capital Management, LLC98,1470.10%US$475KSep 30, 2026
Citigroup Inc81,7180.08%US$396KSep 30, 2026
Rhumbline Advisers69,9190.07%US$338KSep 30, 2026

This page holds 50 of 111 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.24M2.3%US$9.2MJun 30, 2026
iShares Russell 2000 ETF1.35M1.4%US$5.54MJun 30, 2026
Vanguard Extended Market Index Fund652K0.67%US$2.68MJun 30, 2026
Fidelity Small Cap Index Fund584K0.60%US$2.17MJul 31, 2026
iShares Russell 2000 Growth ETF503K0.52%US$2.07MJun 30, 2026
Fidelity Extended Market Index Fund224K0.23%US$978KMay 31, 2026
iShares Micro-Cap ETF180K0.19%US$739KJun 30, 2026
Schwab Small-Cap Index Fund130K0.13%US$482KJul 31, 2026
Master Small Cap Index Series100K0.10%US$411KJun 30, 2026
Fidelity Total Market Index Fund95,0020.10%US$414KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nuveen Small Cap Blend Index Fund71,3430.07%US$265KJul 31, 2026
Fidelity Series Total Market Index Fund66,8100.07%US$291KMay 31, 2026
EQ/2000 Managed Volatility Portfolio58,4110.06%US$240KJun 30, 2026
Fidelity Small Cap Growth Index Fund49,8810.05%US$205KJun 30, 2026
Fidelity Nasdaq Composite Index Fund45,6720.05%US$199KMay 31, 2026
EA Bridgeway Omni Small-Cap Value ETF42,0650.04%US$173KJun 30, 2026
LVIP State Street Small-Cap Index Fund40,0000.04%US$164KJun 30, 2026
Schwab Total Stock Market Index Fund35,0000.04%US$130KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund34,9340.04%US$144KJun 30, 2026
Vanguard Balanced Index Fund32,0830.03%US$132KJun 30, 2026
Global X Russell 2000 ETF25,5970.03%US$94,965Jul 31, 2026
Small Cap Index Fund24,8660.03%US$102KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio23,2000.02%US$95,352Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio20,5250.02%US$84,358Jun 30, 2026
MetLife Russell 2000 Index Portfolio18,2640.02%US$75,065Jun 30, 2026
Small-Cap Index Portfolio15,4850.02%US$63,643Jun 30, 2026
NVIT Small Cap Index Fund12,1420.01%US$49,904Jun 30, 2026
1290 VT Micro Cap Portfolio12,0720.01%US$49,616Jun 30, 2026
Small Cap Index Trust11,9960.01%US$49,304Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund9,8170.01%US$36,421Jul 31, 2026
EQ/Small Company Index Portfolio8,460<0.01%US$34,771Jun 30, 2026
EQ/AB Small Cap Growth Portfolio8,460<0.01%US$34,771Jun 30, 2026
DWS Small Cap Index VIP8,420<0.01%US$34,606Jun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio8,183<0.01%US$33,632Jun 30, 2026
T. Rowe Price Small-Cap Index Fund8,074<0.01%US$33,184Jun 30, 2026
Victory Extended Market Index Fund7,624<0.01%US$28,285Jul 31, 2026
BlackRock Small Cap Index V.I. Fund7,308<0.01%US$30,036Jun 30, 2026
Voya RussellTM Small Cap Index Portfolio6,884<0.01%US$28,293Jun 30, 2026
SA Small Cap Index Portfolio6,271<0.01%US$23,265Jul 31, 2026
PD Small-Cap Growth Index Portfolio4,954<0.01%US$20,361Jun 30, 2026
CVT Russell 2000 Small Cap Index Portfolio4,860<0.01%US$19,975Jun 30, 2026
Nationwide Small Cap Index Fund4,814<0.01%US$17,860Jul 31, 2026
Venerable Small Cap Index Fund4,282<0.01%US$17,599Jun 30, 2026
Voya VACS Index Series SC Portfolio4,133<0.01%US$16,987Jun 30, 2026
SmallCap Growth Fund I4,095<0.01%US$15,192Jul 31, 2026
Strategic Equity Allocation Trust2,621<0.01%US$10,772Jun 30, 2026
EQ/Franklin Small Cap Value Managed Volatility Portfolio1,850<0.01%US$7,604Jun 30, 2026
Penn Series Small Cap Index Fund1,600<0.01%US$6,576Jun 30, 2026
State Street Total Return V.I.S. Fund1,352<0.01%US$5,557Jun 30, 2026
Total Stock Market Index Trust1,261<0.01%US$5,183Jun 30, 2026

This page holds 50 of 58 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Magrath George
Director, Officer: Chief Executive Officer
Sale28,258USD 3.90US$110KNov 3, 2026
Magrath George
Director, Officer: Chief Executive Officer
Sale9,591USD 3.58US$34,384Oct 23, 2026
Gagnon Robert E.
Officer: Chief Financial Officer
Sale14,000USD 3.55US$49,650Oct 23, 2026
Yerxa Benjamin R
Director, Officer: President
Sale7,669USD 3.55US$27,236Oct 23, 2026
Yerxa Benjamin R
Director, Officer: President
Sale25,520USD 3.53US$90,129Oct 23, 2026
Schachle Joseph K
Officer: Chief Operating Officer
Sale4,767USD 3.56US$16,994Oct 23, 2026
Foundation Fighting Blindness Retinal Degeneration Fund
Director, Other: See Remarks
Sale556,000USD 4.96US$2.76MSep 30, 2026
Gagnon Robert E.
Officer: Chief Financial Officer
Sale28,000USD 4.54US$127KSep 3, 2026
Gagnon Robert E.
Officer: Chief Financial Officer
Sale7,783USD 2.95US$22,960Jul 23, 2026
Magrath George
Director, Officer: Chief Executive Officer
Sale9,475USD 2.95US$27,951Jul 23, 2026
All 19 trades
TradeTradeSharesPriceValueDate
Schachle Joseph K
Officer: Chief Operating Officer
Sale4,644USD 2.94US$13,653Jul 23, 2026
Yerxa Benjamin R
Director, Officer: President
Sale7,429USD 2.97US$22,064Jul 23, 2026
Foundation Fighting Blindness Retinal Degeneration Fund
Director, Other: See Remarks
Sale1,700,000USD 4.35US$7.39MMay 18, 2026
Gagnon Robert E.
Officer: Chief Financial Officer
Sale7,842USD 5.18US$40,622Apr 23, 2026
Jayagopal Ashwath
Officer: Chief Scientific & Dev. Ofc.
Sale7,542USD 5.19US$39,143Apr 23, 2026
Magrath George
Director, Officer: Chief Executive Officer
Sale9,511USD 5.22US$49,647Apr 23, 2026
Zaremba Rabourn Amy
Officer: Head of Fin. Quality Assurance
Sale1,641USD 5.20US$8,533Apr 23, 2026
Schachle Joseph K
Officer: Chief Operating Officer
Sale4,697USD 5.22US$24,518Apr 23, 2026
Yerxa Benjamin R
Director, Officer: President
Sale7,470USD 5.24US$39,143Apr 23, 2026

Big stakes

StakeStakeSharesDateFiling
Perceptive Advisors LLC9.99%10.1MSep 30, 2026Schedule 13G
Balyasny Asset Management L.P.7.36%6.12MSep 30, 2026Schedule 13G
Cormorant Asset Management, LP6.61%5.5MSep 30, 2026Schedule 13G
Nantahala Capital Management, LLC6.51%4.84MMar 31, 2026Schedule 13G
Caligan Partners LP6.20%5.96MSep 30, 2026Schedule 13G
BlackRock, Inc.6.10%5.04MSep 30, 2026Schedule 13G
Boxer Capital Management, LLC5.40%4.53MSep 30, 2026Schedule 13G
Foundation Fighting Blindness Retinal Degeneration Fund4.66%3.79MMay 18, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Richard Rodgers
Other companies: Novavax, Inc. (Director · Since at least Oct 29, 2022); Ardelyx, Inc. (Director · Since at least Jun 18, 2014); Sagimet Biosciences Inc. - Series A (Director · Jul 13, 2023 – Jul 18, 2023 · Past); Tesaro Inc (Executive VP & CFO · Jun 27, 2012 – Mar 6, 2013 · Past); Abraxis BioScience Inc (Senior Vice President and CFO · Jul 9, 2009 – Jul 13, 2009 · Past); Mgi Pharma Inc (Sr. VP and Controller · Jul 15, 2006 – Jan 28, 2008 · Past)
Director · Since at least Dec 2, 2014
Robert Gagnon
Other companies: Purple Biotech Ltd. (Board Member · Since at least Mar 18, 2026); Bone Biologics Corp (Director · Since at least Jan 8, 2024); Verastem, Inc. (Director · Since at least Aug 28, 2018); Harvard Bioscience, Inc. (Director · Since at least Nov 18, 2013); Clean Harbors, Inc. (EVP CFO and Treasurer · Aug 20, 2012 – Sep 11, 2012 · Past); Biogen Inc. (Vice President, Finance · Nov 3, 2010 – Feb 28, 2012 · Past)
Chief Financial Officer · Since at least Sep 2, 2025
Adrienne L. Graves
Other companies: Harrow, Inc. (Member, Board of Directors, Independent Director · Since at least Jan 26, 2024); Ocular Therapeutix, Inc. (Director · Since at least Jul 10, 2023); IVERIC bio Inc (Director · Dec 12, 2018 – Jul 11, 2023 · Past); Akorn Inc (Director · Jul 1, 2016 – May 9, 2019 · Past); TearLab Corporation (TEAR) (Director · Jun 24, 2016 – Jun 24, 2016 · Past)
Director · Since at least Oct 22, 2024
James S. Manuso
Other companies: TuHURA Biosciences, Inc. (Chairman of the Board of Directors · Since at least Oct 18, 2024); RespireRx Pharmaceuticals Inc (President and CEO, Director · Feb 4, 2016 – Sep 13, 2017 · Past); Astex Pharmaceuticals Inc (Chief Executive Officer, Director · Mar 15, 2010 – Oct 11, 2013 · Past)
Director · Since at least Nov 5, 2020
Cam Gallagher
Other companies: Zentalis Pharmaceuticals, Inc. (President, Interim CFO, Director · Feb 1, 2024 – May 31, 2024 · Past)
Director · Since at least Jun 11, 2024
Ely Benaim
Other companies: NovoCure Limited (Chief Medical Officer · Jul 24, 2019 – Jan 6, 2023 · Past)
Chief Medical Officer · Feb 2, 2015 – Feb 28, 2019 · Past
Jean Bennett
Other companies: Regenxbio Inc. (Director · Since at least Sep 3, 2021)
Director · Since at least Oct 22, 2024
Lisa Nolan
Other companies: Relmada Therapeutics, Inc. (Chief Business Officer · Dec 14, 2015 – Dec 14, 2015 · Past)
Chief Business Officer · Jul 6, 2016 – Feb 28, 2019 · Past
Nirav Jhaveri
Other companies: Longeveron Inc. (Chief Financial Officer · Since at least Aug 17, 2026)
Chief Financial Officer · Feb 12, 2024 – Mar 13, 2025 · Past
Alan R MeyerDirector · Nov 5, 2020 – Nov 19, 2020 · Past
All 27 people
PersonSeat
Andrew MurphyChief Scientific Officer · Since at least Oct 29, 2026
Ashwath JayagopalChief Scientific & Dev. Ofc. · Since at least Feb 12, 2024
Ben YerxaPresident, Director · Since at least Apr 23, 2026
Charles BeeverDirector · Jun 6, 2019 – Jun 6, 2019 · Past
Chris ErnstChief Technology Officer · Since at least Nov 5, 2026
Freddie Ann HoffmanDirector · Jun 11, 2007 – Jun 1, 2009 · Past
George MagrathChief Executive Officer · Since at least Nov 1, 2023
Jay PeposeDirector · Apr 8, 2022 – Jun 11, 2024 · Past
Joe SchachleChief Operating Officer · Since at least Jan 22, 2026
Mark CarthyDirector · Feb 26, 2014 – Apr 11, 2017 · Past
Rabourn Amy ZarembaHead of Fin. Quality Assurance · Since at least Nov 11, 2020
Ronil A PatelChief Business Officer · Apr 24, 2023 – Jan 10, 2024 · Past
Sally TuckerChief Medical Officer · Since at least Nov 5, 2026
Sarah TullerChief Regulatory Officer · Since at least Nov 5, 2026
Sean AinsworthDirector · Since at least Apr 30, 2025
Susan BentonDirector · Since at least Nov 5, 2020
Young Soon ParkDirector · Sep 12, 2005 – Dec 11, 2006 · Past

Open People

Log in to ask 6ix AI your own questions about Opus Genetics, Inc.